Novo shares fell 5% last Friday due to underwhelming results for monlunabant in its Phase 2a Food and Drug Administration ...

The company imports some of its active pharmaceutical ingredient, or semaglutide, into the U.S. for its blockbuster diabetes ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) is a terrific stock for many reasons. The company continues to deliver ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug ...

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and ...

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...